Literature DB >> 25600190

Understanding organ dysfunction in thrombotic thrombocytopenic purpura.

Pier Mannuccio Mannucci1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 25600190     DOI： 10.1007/s00134-014-3630-z

Source DB:  PubMed          Journal:  Intensive Care Med        ISSN： 0342-4642            Impact factor:   17.440


× No keyword cloud information.
  16 in total

1.  Preemptive rituximab infusions after remission efficiently prevent relapses in acquired thrombotic thrombocytopenic purpura.

Authors:  Miguel Hie; Julie Gay; Lionel Galicier; François Provôt; Claire Presne; Pascale Poullin; Guy Bonmarchand; Alain Wynckel; Ygal Benhamou; Philippe Vanhille; Aude Servais; Dominique Bordessoule; Jean-Philippe Coindre; Mohamed Hamidou; Jean-Paul Vernant; Agnès Veyradier; Paul Coppo
Journal:  Blood       Date:  2014-05-28       Impact factor: 22.113

2.  Structure of von Willebrand factor-cleaving protease (ADAMTS13), a metalloprotease involved in thrombotic thrombocytopenic purpura.

Authors:  X Zheng; D Chung; T K Takayama; E M Majerus; J E Sadler; K Fujikawa
Journal:  J Biol Chem       Date:  2001-09-13       Impact factor: 5.157

3.  Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura. Canadian Apheresis Study Group.

Authors:  G A Rock; K H Shumak; N A Buskard; V S Blanchette; J G Kelton; R C Nair; R A Spasoff
Journal:  N Engl J Med       Date:  1991-08-08       Impact factor: 91.245

4.  The use of intermediate purity factor VIII concentrate BPL 8Y as prophylaxis and treatment in congenital thrombotic thrombocytopenic purpura.

Authors:  Marie Scully; Michael Gattens; Kate Khair; Ri Liesner
Journal:  Br J Haematol       Date:  2006-08-22       Impact factor: 6.998

5.  Mutations in a member of the ADAMTS gene family cause thrombotic thrombocytopenic purpura.

Authors:  G G Levy; W C Nichols; E C Lian; T Foroud; J N McClintick; B M McGee; A Y Yang; D R Siemieniak; K R Stark; R Gruppo; R Sarode; S B Shurin; V Chandrasekaran; S P Stabler; H Sabio; E E Bouhassira; J D Upshaw; D Ginsburg; H M Tsai
Journal:  Nature       Date:  2001-10-04       Impact factor: 49.962

6.  Deficient activity of von Willebrand factor-cleaving protease in chronic relapsing thrombotic thrombocytopenic purpura.

Authors:  M Furlan; R Robles; M Solenthaler; M Wassmer; P Sandoz; B Lämmle
Journal:  Blood       Date:  1997-05-01       Impact factor: 22.113

7.  Antibodies to von Willebrand factor-cleaving protease in acute thrombotic thrombocytopenic purpura.

Authors:  H M Tsai; E C Lian
Journal:  N Engl J Med       Date:  1998-11-26       Impact factor: 91.245

8.  Physiologic cleavage of von Willebrand factor by a plasma protease is dependent on its conformation and requires calcium ion.

Authors:  H M Tsai
Journal:  Blood       Date:  1996-05-15       Impact factor: 22.113

9.  Thrombotic thrombocytopenic purpura and pregnancy: presentation, management, and subsequent pregnancy outcomes.

Authors:  Marie Scully; Mari Thomas; Mary Underwood; Henry Watson; Katherine Langley; Raymond S Camilleri; Amanda Clark; Desmond Creagh; Rachel Rayment; Vickie Mcdonald; Ashok Roy; Gillian Evans; Siobhan McGuckin; Fionnuala Ni Ainle; Rhona Maclean; William Lester; Michael Nash; Rosemary Scott; Patrick O Brien
Journal:  Blood       Date:  2014-05-23       Impact factor: 22.113

10.  ADAMTS13 autoantibodies in patients with thrombotic microangiopathies and other immunomediated diseases.

Authors:  Manfred Rieger; Pier Mannuccio Mannucci; Johanna A Kremer Hovinga; Andrea Herzog; Gabi Gerstenbauer; Christian Konetschny; Klaus Zimmermann; Inge Scharrer; Flora Peyvandi; Miriam Galbusera; Giuseppe Remuzzi; Martina Böhm; Barbara Plaimauer; Bernhard Lämmle; Friedrich Scheiflinger
Journal:  Blood       Date:  2005-05-12       Impact factor: 22.113
View more
  9 in total

1.  Severe preeclampsia: what's new in intensive care?

Authors:  Marc Leone; Sharon Einav
Journal:  Intensive Care Med       Date:  2015-03-03       Impact factor: 17.440

2.  Understanding therapeutic targets in thrombotic thrombocytopenic purpura.

Authors:  Bérangère S Joly; Karen Vanhoorelbeke; Agnès Veyradier
Journal:  Intensive Care Med       Date:  2017-01-23       Impact factor: 17.440

3.  Focus on transfusion, bleeding and thrombosis.

Authors:  Elie Azoulay; Yaseen Arabi; Anders Perner
Journal:  Intensive Care Med       Date:  2016-10-25       Impact factor: 17.440

4.  Does this patient with thrombotic thrombocytopenic purpura have a cardiac involvement?

Authors:  Lara Zafrani; Lene Russell; Elie Azoulay
Journal:  Intensive Care Med       Date:  2018-06-04       Impact factor: 17.440

Review 5.  Diagnostic work-up and specific causes of acute kidney injury.

Authors:  Michael Darmon; Marlies Ostermann; Jorge Cerda; Meletios A Dimopoulos; Lui Forni; Eric Hoste; Matthieu Legrand; Nicolas Lerolle; Eric Rondeau; Antoine Schneider; Bertrand Souweine; Miet Schetz
Journal:  Intensive Care Med       Date:  2017-04-25       Impact factor: 17.440

6.  The clinical features of cardiac involvement in patients with severe thrombotic thrombocytopenic purpura.

Authors:  Aude-Marie Fourmont; Lara Zafrani; Eric Mariotte; Lionel Galicier; Bérangère Joly; Sybille Merceron; Rémi Bertinchamp; Virginie Lemiale; Audrey de Jong; Sandrine Valade; Michael Darmon; Agnès Veyradier; Elie Azoulay
Journal:  Intensive Care Med       Date:  2018-05-11       Impact factor: 17.440

7.  Expert statement on the ICU management of patients with thrombotic thrombocytopenic purpura.

Authors:  Elie Azoulay; Philippe R Bauer; Eric Mariotte; Lene Russell; Paul Knoebl; Ignacio Martin-Loeches; Frédéric Pène; Kathryn Puxty; Pedro Povoa; Andreas Barratt-Due; Jose Garnacho-Montero; Julia Wendon; Laveena Munshi; Dominique Benoit; Michael von Bergwelt-Baildon; Marco Maggiorini; Paul Coppo; Spero Cataland; Agnès Veyradier; Andry Van de Louw
Journal:  Intensive Care Med       Date:  2019-10-07       Impact factor: 17.440

Review 8.  Severe Thrombotic Thrombocytopenic Purpura (TTP) with Organ Failure in Critically Ill Patients.

Authors:  Sofiane Fodil; Lara Zafrani
Journal:  J Clin Med       Date:  2022-02-19       Impact factor: 4.241

9.  Outcomes in 1096 patients with severe thrombotic thrombocytopenic purpura before the Caplacizumab era.

Authors:  Andry Van de Louw; Eric Mariotte; Michael Darmon; Austin Cohrs; Douglas Leslie; Elie Azoulay
Journal:  PLoS One       Date:  2021-08-12       Impact factor: 3.240
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.